Infosys Tech and Elan Pharma to Co-Create Solution
Elan Pharmaceuticals, Inc has chosen Infosys Technologies Limited to design and implement the Research Informatics System (RISe), so as to speed up discovery research. The solution will use ‘co-creation engagement model’ that leverages Infosys’ existing intellectual property in this field.
This is a co-creation engagement model wherein Infosys will retain ownership of co-developed IP as part of the implementation. Relevant components of this reference implementation can be reused or repurposed by Infosys to deliver business benefits at other life sciences organizations.
Elan Corporation, a a neuroscience-based biotechnology company, will leverage Infosys’ informatics scientific innovation solution for knowledge collaboration. This will present scientists with new ways to unlock disparate data spread across in-house research labs and other commercial or public sources. This will result in, among other things, a customized registry, and inventory and a workflow management system for biological entities.
"We selected Infosys after a competitive Proof-of-Concept phase during which they fully established their credentials and investments in this changing field of discovery research, and demonstrated flexibility and maturity in terms of rapid application development using Agile and Scrum methodologies," explained Ajay Shah, director, Research Informatics, Elan Pharmaceuticals.
With the new RISe, Elan and its research partners hopes to realize improvements in research productivity through focused and efficient selection of candidate drugs or biologics. It could help link silos of heterogeneous data to contribute to a selection process of biologics. This could reduce time to validate them clinically.
Future versions of the software may also enable integration of RISe with electronic lab notebook and analytical dashboards, for better research knowledge management.
"Elan’s vision to create a scalable research informatics system for scientists to collaborate better, dovetails perfectly with our investments in solutions that improve scientific innovation and our efforts to streamline discovery research," said R Arun Kumar, head of Infosys’ Global Life Sciences Practice, Infosys Technologies.
- Why 2018 Will Belong To Cloud, AI, Blockchain
- Governance, Risk and Compliance- Trends and Predictions
- How CIOs Can Ensure A Seat At The Strategy Table
- Key Challenges For Infosys' New CEO Salil Parekh
- Infosys Names Capgemini's Salil Parekh As New CEO
- Are Brands Getting Too Late To Digitize?
- What’s Up With Mid-level IT leaders?
- The Age of Cognition Is Coming
- Leveraging Digital Technologies For Manufacturing
- Five Big Data Trends To Influence AI In 2018